Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
vatreptacog alfa (activated)
DRUG
3 trials
Sponsors
Novo Nordisk A/S
Conditions
Congenital Bleeding Disorder
Haemophilia A
Haemophilia A With Inhibitors
Haemophilia B
Haemophilia B With Inhibitors
Healthy
Phase 1
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Completed
NCT00822185
Novo Nordisk A/S
Congenital Bleeding Disorder, Healthy
Start: 2009-01-31
End: 2009-07-31
Updated: 2015-01-05
Phase 2
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Completed
NCT00486278
Novo Nordisk A/S
Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
Start: 2007-06-30
End: 2010-06-30
Updated: 2017-03-07
Phase 3
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Completed
NCT01392547
Novo Nordisk A/S
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Start: 2011-07-31
End: 2012-08-31
Updated: 2017-05-15
Related Papers
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
2012-01-01
27 citations